ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The EMA covers 27 countries in the European Union, as well as Iceland, Norway and Liechtenstein.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX: